Exploring the Role of Progression Free Survival in Chemotherapy Protocol: A Literatur Review
Telaah Pustaka Penilaian Progression Free Survival Sebagai Parameter Klinis Tata Terapi Kanker
Keywords:
chemotherapy, clinical endpoint, tumor progressionAbstract
Progression-Free Survival (PFS) measures cancer patients' resistance to tumor progression. This alternative measurement is effective in assessing the performance of cancer therapy protocols and may serve an evidence for evaluating the quality of life of patients and planning follow-up treatments. Here in, we review a number of PFS data publications for drugs used in cancer therapy. The review involves ten scientific articles met the inclusion criteria provided by the PubMed database. Our finding present the optimal performance of chemotherapy protocols in preventing disease progression in seven various cancer populations. The highest PFS values for each cancer such as: crizotinib for lung cancer (28.71 months), enzalutamide for prostate cancer (7.1 months), pamiparib for stomach cancer (3.7 months), anlotinib for liver cancer (4.2 months), irinotecan plus raltitrexed for esophageal cancer (3.91 months), folfoxiri plus bevacizumab for metastatic colorectal cancer (10.7 months), and paclitaxel plus vistusertib for ovarian carcinoma (4.5 months).
References
L. M. Hess, A. Brnabic, O. Mason, P. Lee, dan S. Barker, “Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology,” Journal of Cancer, vol. 10, no. 16, hlm. 3717, 2019.
S. P. Harahap, N. Sutandyo, C. M. Rumende, dan H. Shatri, “Perbandingan Rejimen Kemoterapi Cisplatin Etoposide dengan Cisplatin-Docetaxel dalam Hal Kesintasan 2 Tahun dan Progression-Free Survival Pasien Kanker Paru Stadium Lanjut Jenis Non-Small Cell,” Jurnal Penyakit Dalam Indonesia| Vol, vol. 3, no. 2, 2016.
C. Irawan, R. Steven, R. G. Gunarsa, dan J. B. Tenggara, “Outcome Result of Acute Myeloid Leukemia Undergoing Treatment in Semi-Isolation Chemotherapy Ward,” Jurnal Penyakit Dalam Indonesia, vol. 9, no. 3, hlm. 5, 2022.
N. Sutandyo, A. Hanafi, dan M. Jayusman, “Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population,” Zhongguo fei ai za zhi = Chinese journal of lung cancer, vol. 22, no. 9, hlm. 562–567, Sep 2019, doi: 10.3779/j.issn.1009-3419.2019.09.02.
S. Mailankody dan V. Prasad, “Five years of cancer drug approvals: innovation, efficacy, and costs,” JAMA oncology, vol. 1, no. 4, hlm. 539–540, 2015.
A. Amila, E. Sembiring, dan N. Aryani, “Deteksi Dini Dan Pencegahan Penyakit Degeneratif Pada Masyarakat Wilayah Mutiara Home Care,” Jurnal Kreativitas Pengabdian Kepada Masyarakat (Pkm), vol. 4, no. 1, hlm. 102–112, 2021, doi: 10.33024/jkpm.v4i1.3441.
X. Paoletti dkk., “Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis,” JAMA network open, vol. 3, no. 1, hlm. e1918939–e1918939, 2020.
L. Sun, Y. Zhu, Q. Qian, dan L. Tang, “Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis,” Medicine, vol. 97, no. 26, 2018.
Y. Yang dkk., “Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.,” Signal transduction and targeted therapy, vol. 8, no. 1, hlm. 301, 2023, doi: 10.1038/s41392-023-01538-w.
B. C. Cho dkk., “ Lazertinib Versus Gefitinib as First-line Treatment in Patients With EGFR -mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results From LASER301 ,” Journal of Clinical Oncology, vol. 41, no. 26, 2023, doi: 10.1200/jco.23.00515.
V. M. Macaulay dkk., “A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer,” British Journal of Cancer, no. July, 2023, doi: 10.1038/s41416-023-02380-1.
D. C. Smith dkk., “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.,” Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 31, no. 4, hlm. 412–419, Feb 2013, doi: 10.1200/JCO.2012.45.0494.
F. Ciardiello dkk., “Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results,” Cancer Medicine, no. March, hlm. 13145–13154, 2023, doi: 10.1002/cam4.5997.
K. Shitara dkk., “Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS),” Journal of Cancer Research and Clinical Oncology, vol. 149, no. 11, hlm. 9361–9374, 2023, doi: 10.1007/s00432-023-04813-z.
M. Kang, F. Xue, S. Xu, J. Shi, dan Y. Mo, “Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study.,” Radiology and oncology, vol. 57, no. 3, hlm. 405–410, Sep 2023, doi: 10.2478/raon-2023-0036.
X. Dai dkk., “Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study,” Cancer Medicine, no. March, hlm. 16108–16118, 2023, doi: 10.1002/cam4.6264.
S. Stintzing dkk., “ FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study ,” Journal of Clinical Oncology, vol. 41, no. 25, 2023, doi: 10.1200/jco.22.01420.
S. Banerjee dkk., “Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.,” JAMA oncology, vol. 9, no. 5, hlm. 675–682, Mei 2023, doi: 10.1001/jamaoncol.2022.7966.
H.-Y. Tu, Y.-C. Zhang, dan Y.-L. Wu, “A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology,” Translational Cancer Research, vol. 6, no. Supplement 2, hlm. 292–295, 2017.
Y. Ma dkk., “First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements,” European Journal of Cancer, vol. 173, hlm. 238–249, 2022, doi: https://doi.org/10.1016/j.ejca.2022.06.037.
J. Guerrero, I. E. Alfaro, F. Gómez, A. A. Protter, dan S. Bernales, “Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.,” The Prostate, vol. 73, no. 12, hlm. 1291–1305, Sep 2013, doi: 10.1002/pros.22674.
M. Kang, C. W. Jeong, C. Kwak, J. H. Ku, dan H. H. Kim, “Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials.,” Oncotarget, vol. 8, no. 35, hlm. 59690–59697, Agu 2017, doi: 10.18632/oncotarget.17741.
B. L. Maughan, B. Luber, R. Nadal, dan E. S. Antonarakis, “Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.,” The Prostate, vol. 77, no. 1, hlm. 33–40, Jan 2017, doi: 10.1002/pros.23246.
X. Wu dkk., “Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.,” Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 4, hlm. 653–661, Feb 2022, doi: 10.1158/1078-0432.CCR-21-1186.
A. González-Martín dkk., “Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer,” New England Journal of Medicine, vol. 381, no. 25, hlm. 2391–2402, Sep 2019, doi: 10.1056/NEJMoa1910962.
B. Xu dkk., “Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.,” Cancer medicine, vol. 10, no. 1, hlm. 109–118, Jan 2021, doi: 10.1002/cam4.3575.
J. K. Litton dkk., “Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.,” The New England journal of medicine, vol. 379, no. 8, hlm. 753–763, Agu 2018, doi: 10.1056/NEJMoa1802905.
Y.-J. Bang dkk., “Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.,” Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 33, no. 33, hlm. 3858–3865, Nov 2015, doi: 10.1200/JCO.2014.60.0320.
C. Xie dkk., “Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.,” Cancer science, vol. 109, no. 4, hlm. 1207–1219, Apr 2018, doi: 10.1111/cas.13536.
S. Taurin dkk., “Abstract 3244: Treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2,” Cancer Research, vol. 77, no. 13_Supplement, hlm. 3244, Jul 2017, doi: 10.1158/1538-7445.AM2017-3244.
B. Han dkk., “Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).,” British journal of cancer, vol. 118, no. 5, hlm. 654–661, Mar 2018, doi: 10.1038/bjc.2017.478.
C. Carnaghi dkk., “Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.,” Annals of oncology : official journal of the European Society for Medical Oncology, vol. 13, no. 9, hlm. 1424–1429, Sep 2002, doi: 10.1093/annonc/mdf229.
J. Aparicio dkk., “Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.,” Annals of oncology : official journal of the European Society for Medical Oncology, vol. 14, no. 7, hlm. 1121–1125, Jul 2003, doi: 10.1093/annonc/mdg285.
X. Wang, X. Wang, dan J. Huang, “Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma.,” Thoracic cancer, vol. 7, no. 2, hlm. 246–250, Mar 2016, doi: 10.1111/1759-7714.12323.
M. Liu dkk., “Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer.,” Anti-cancer drugs, vol. 31, no. 4, hlm. 403–410, Apr 2020, doi: 10.1097/CAD.0000000000000891.
G. Masi dkk., “Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.,” The Lancet. Oncology, vol. 11, no. 9, hlm. 845–852, Sep 2010, doi: 10.1016/S1470-2045(10)70175-3.
A. Falcone dkk., “Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.,” Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 25, no. 13, hlm. 1670–1676, Mei 2007, doi: 10.1200/JCO.2006.09.0928.
F. Loupakis dkk., “Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.,” The New England journal of medicine, vol. 371, no. 17, hlm. 1609–1618, Okt 2014, doi: 10.1056/NEJMoa1403108.
B. Basu dkk., “Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.,” Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, no. 9, hlm. 1918–1925, Sep 2018, doi: 10.1093/annonc/mdy245.
S. S. Zahrah, R. Wijayatri, I. W. Hidayat, A. Syarifuddin, dan S. B. Santoso, “From the Genetic Mutation to the Specific Pathologies,” dalam Proceedings of the 4th Borobudur International Symposium on Humanities and Social Science 2022 (BIS-HSS 2022), vol. 778, Z. B. Pambuko, M. Setiyo, C. B. E. Praja, A. Setiawan, F. Yuliastuti, L. Muliawanti, dan V. S. Dewi, Ed., dalam Advances in Social Science, Education and Humanities Research, vol. 778. , Paris: Atlantis Press SARL, 2024, hlm. 439–447. doi: 10.2991/978-2-38476-118-0_49.
D. N. Hikmah, A. Syarifuddin, S. B. Santoso, R. Wijayatri, dan I. W. Hidayat, “The Role of Genetic Mutation on Schizophrenia: A Basic Review Prior to Pharmacogenomics,” dalam Proceedings of the 4th Borobudur International Symposium on Humanities and Social Science 2022 (BIS-HSS 2022), vol. 778, Z. B. Pambuko, M. Setiyo, C. B. E. Praja, A. Setiawan, F. Yuliastuti, L. Muliawanti, dan V. S. Dewi, Ed., dalam Advances in Social Science, Education and Humanities Research, vol. 778. , Paris: Atlantis Press SARL, 2024, hlm. 835–847. doi: 10.2991/978-2-38476-118-0_96.
S. B. Santoso, P. Pribadi, dan L. M. Irham, “Isoniazid-induced liver injury risk level in different variants of N-acetyltransferase 2 (NAT2) polymorphisms: A literature review,” PHAR, vol. 70, no. 4, hlm. 973–981, Okt 2023, doi: 10.3897/pharmacia.70.e109869.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
